VF
AVTX icon

Virtu Financial’s Avalo Therapeutics AVTX Stock Holding History

Virtu Financial’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-772
Closed -$22K – 1562
2023
Q3 		$22K Buy
772
+636
+468% +$28.4K ﹤0.01% 996
2023
Q2 		$12K Buy
+136
New +$91.6K ﹤0.01% 1330
2022
Q1 		– Sell
-11
Closed -$56K – 1489
2021
Q4 		$56K Buy
11
+2
+22% +$12K 0.01% 1315
2021
Q3 		$56K Sell
9
-11
-55% -$89.2K ﹤0.01% 1254
2021
Q2 		$189K Buy
+20
New +$168K 0.02% 1018
2019
Q3 		– Sell
-3
Closed -$54K – 1416
2019
Q2 		$54K Sell
3
-4
-57% -$60.6K ﹤0.01% 1220
2019
Q1 		$109K Buy
+7
New +$105K 0.01% 1117
2018
Q2 		– Sell
-8
Closed -$103K – 1972
2018
Q1 		$103K Sell
8
-53
-87% -$597K 0.01% 1570
2017
Q4 		$560K Buy
+61
New +$263K 0.03% 756

Other funds holding AVTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
N
Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Virtu Financial's AVTX Position: Q4 2023 in Review

Virtu Financial sold out of Avalo Therapeutics (AVTX) in Q4 2023, closing a stake of 772 shares — an estimated $22K sold.

Virtu Financial first reported a position in AVTX in Q4 2017 and held it in 9 quarters. The position peaked at $560K in Q4 2017. 12 funds tracked by Wall St. Rank hold AVTX as of Q4 2023.

  • Virtu Financial reported no remaining Avalo Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Virtu Financial sold 772 Avalo Therapeutics shares in Q4 2023, an estimated $22K.
  • Virtu Financial first reported a position in Avalo Therapeutics in Q4 2017 and held it in 9 quarters.
  • Virtu Financial's Avalo Therapeutics position peaked at $560K in Q4 2017.
  • 12 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q4 2023.

Based on Virtu Financial's 13F filing for Q4 2023, filed 26 Feb 2024.